HTAtlas
← Back to explore

Template for OBMEA data collection agreements

Templatevalidated

A ready-to-use template that helps stakeholders create formal agreements on how data will be collected for outcomes-based managed entry agreements (OBMEAs) for rare disease treatments.

At a glance

Use when

Setting up an OBMEA for a rare disease treatment where real-world outcomes will inform reimbursement or access decisions

Avoid when

When data collection is not required, or when stakeholders cannot agree on outcomes or responsibilities

Inputs

Details of the treatment, rare disease context, involved stakeholders, data sources, and outcome measures

Outputs

A formalized data collection agreement outlining responsibilities, data specifications, timelines, and governance

How it works

This template structures the data collection agreement among stakeholders involved in an OBMEA, specifying roles, data types, collection methods, timelines, data ownership, and reporting requirements, ensuring alignment and transparency in real-world evidence generation for rare disease therapies.

Project
IMPACT HTA
Funding
Horizon 2020
Project status
Completed 2021
HTA domains
Aspects Beyond HTA
Categories
Pricing/Payer
Technology
Medicines
Assumptions
Stakeholders are willing to collaborate; data sources are accessible; outcomes are measurable and agreed upon
Strengths
Promotes clarity and accountability among stakeholders; supports consistent and reliable data collection; adaptable to various rare diseases and treatments
Limitations
May require legal review; less effective if stakeholder alignment is weak; not suitable for non-outcomes-based agreements
Also known as
OBMEA Data Collection Agreement Template

Questions this answers

Similar by meaning

Beta record. Based on the original catalogue summary; primary-source enrichment pending.